Page 92 - 2023-05-中国全科医学
P. 92

2023年2月   第26卷   第5期                                 http: //www.chinagp.net   E-mail: zgqkyx@chinagp.net.cn  ·605·

               1948-1950. DOI:10.3969/j.issn.1003-6350.2020.15.012.  drug-resistant tuberculosis[J]. China Journal of Pharmaceutical
           [17]马清艳 . 常规化疗联合莫西沙星或左氧氟沙星治疗耐多药肺结                        Economics,2021,16(3):88-90.
               核的临床疗效对比[J]. 医学研究与教育,2021,38(6):                [26]周海东 . 含利奈唑胺的联合用药方案治疗耐多药结核病患者
               22-26. DOI:10.3969/j.issn.1674-490X.2021.06.004.     的效果分析[J].  中国医药指南,2021,19(21):44-45.
               MA  Q  Y.  Comparison  of  clinical  efficacy  of  conventional   DOI:10.15912/j.cnki.gocm.2021.21.020.
               chemotherapy combined with moxifloxacin or levofloxacin in   ZHOU H D. Effect analysis of the combination of linezolid in the
               the treatment of patient with multi-drug resistant pulmonary   treatment of patients with multidrug-resistant tuberculosis[J].
               tuberculosis[J]. Medical Research and Education,2021,38(6):  Guide of China Medicine,2021,19(21):44-45. DOI:
               22-26. DOI:10.3969/j.issn.1674-490X.2021.06.004.     10.15912/j.cnki.gocm.2021.21.020.
           [18]KANG Y A,SHIM T S,KOH W J,et al. Choice between   [27]雷一凡,郑新杰,甘先锋,等 . 强化期含利奈唑胺方案治疗耐
               levofloxacin and moxifloxacin and multidrug-resistant tuberculosis   多药结核病的临床观察[J]. 临床肺科杂志,2021,26(4):
               treatment outcomes[J]. Ann Am Thorac Soc,2016,13(3):  542-547.
               364-370. DOI:10.1513/AnnalsATS.201510-690BC.         LEI Y F,ZHENG X J,GAN X F,et al. Clinical observation of
           [19]KOH  W  J,LEE  S  H,KANG  Y  A,et  al.  Comparison  of   intensive phase with linezolid in treatment of multidrug resistant
               levofloxacin  versus  moxifloxacin  for  multidrug-resistant   tuberculosis[J]. Journal of Clinical Pulmonary Medicine,2021,
               tuberculosis[J]. Am J Respir Crit Care Med,2013,188(7):  26(4):542-547.
               858-864. DOI:10.1164/rccm.201303-0604OC.        [28]崔丹,冯秀莉,李志惠,等 .  利奈唑胺与微卡联用对耐多
           [20]梁丽丽,刘新,马芸 . 联合应用莫西沙星或左氧氟沙星治疗耐                        药肺结核的免疫功能影响及临床疗效分析[J].  解放军预
               多药肺结核疗效研究[J]. 中国全科医学,2011,14(13):                    防 医 学 杂 志,2020,38(6):61-63. DOI:10.13704/j.cnki.
               1451-1453,1458. DOI:10.3969/j.issn.1007-9572.2011.13.020.  jyyx.2020.06.024.
               LIANG L L,LIU X,MA Y. Effects of anti-tuberculosis containing   [29]林海鸥,范常龙,李秀萍,等 .  利奈唑胺治疗耐多药结核
               with moxifloxacin or levofloxacin on multidrug resistant pulmonary   病 临 床 疗 效 分 析[J].  医 药 论 坛 杂 志,2019,40(11):
               tuberculosis[J]. Chinese General Practice,2011,14(13):  76-78,82.
               1451-1453,1458. DOI:10.3969/j.issn.1007-9572.2011.13.020.  LIN H O,FAN C L,LI X P,et al. Clinical efficacy of linezolid
           [21]张伯鹏,赵艳,张建伟 . 莫西沙星治疗耐多药肺结核病临床                         in treatment of multidrug-resistant tuberculosis[J]. Journal of
               效果观察[J].  临床肺科杂志,2014,19(6):1126-1128.               Medical Forum,2019,40(11):76-78,82.
               DOI:10.3969/j.issn.1009-6663.2014.06.062.       [30]TANG S J,YAO L,HAO X H,et al. Efficacy,safety and
           [22]庄桂龙,李国航,赵蔚 . 左氧氟沙星辅助治疗耐多药肺结核的                        tolerability of linezolid for the treatment of XDR-TB:a study in
               临床效果并进行药学分析[J]. 中外医疗,2021,40(10):                    China[J]. Eur Respir J,2015,45(1):161-170. DOI:
               94-96. DOI:10.16662/j.cnki.1674-0742.2021.10.094.    10.1183/09031936.00035114.
               ZHUANG  G  L,LI  G  H,ZHAO  W.  The  clinical  effect  of   [31]张喆. 利奈唑胺治疗耐多药结核病临床疗效分析[J]. 健康之友,
               levofloxacin  in  adjuvant  treatment  of  multi-drug  resistant   2020,31(14):78.
               tuberculosis and its pharmaceutical analysis[J]. China & Foreign   [32]吴雅清 . 利奈唑胺联合标准化化疗方案治疗耐多药肺结核的临
               Medical Treatment,2021,40(10):94-96. DOI:10.16662/j.  床效果观察[J].  中国实用医药,2022,17(1):163-165.
               cnki.1674-0742.2021.10.094.                          DOI:10.14163/j.cnki.11-5547/r.2022.01.062.
           [23]张园,龙琳,徐淑婷 . 吡嗪酰胺联合左氧氟沙星治疗耐多药肺                   [33]曾安津,范天琼,杨成明,等 . 利奈唑胺联合环丝氨酸治疗耐
               结核的效果观察[J]. 临床医学工程,2021,28(6):781-                   多药肺结核患者的临床效果[J]. 中国当代医药,2021,28(22):
               782.                                                 194-196,200.
               ZHANG Y,LONG L,XU S T. Observation on the effect of   ZENG A J,FAN T Q,YANG C M,et al. Clinical effect of
               pyrazinamide combined with levofloxacin in the treatment of   Linezolid combined with Cycloserine in the treatment of patients with
               multidrug-resistant pulmonary tuberculosis[J]. Clinical Medicine   multi-drug resistant pulmonary tuberculosis[J]. China Modern
               & Engineering,2021,28(6):781-782.                    Medicine,2021,28(22):194-196,200.
           [24]吴成波 . 左氧氟沙星治疗耐多药肺结核的效果与安全性[J].                  [34]邹广顺,刘辉 . 利奈唑胺治疗耐多药和广泛耐药肺结核的疗效
               中 国 当 代 医 药,2020,27(9):44-46. DOI:10.3969/j.         和安全性[J]. 中国医药指南,2021,19(6):96-97. DOI:
               issn.1674-4721.2020.09.013.                          10.15912/j.cnki.gocm.2021.06.045.
               WU C B. Effect and safety of Levofloxacin in the treatment of   ZOU G S,LIU H. Efficacy and safety of linezolid in the treatment
               multidrug-resistant pulmonary tuberculosis[J]. China Modern   of multidrug-resistant and extensively drug-resistant pulmonary
               Medicine,2020,27(9):44-46. DOI:10.3969/j.issn.1674-  tuberculosis[J]. Guide of China Medicine,2021,19(6):
               4721.2020.09.013.                                    96-97. DOI:10.15912/j.cnki.gocm.2021.06.045.
           [25]梁慧影 . 含左氧氟沙星抗结核方案对耐多药肺结核患者痰培养                   [35]DU Y D,QIU C,CHEN X H,et al. Treatment outcome of a
               转阴率的影响[J]. 中国药物经济学,2021,16(3):88-90.                 shorter regimen containing clofazimine for multidrug-resistant
               LIANG H Y. Effect of levofloxacin-containing anti-tuberculosis   tuberculosis:a randomized control trial in China[J]. Clin Infect
               program on the negative rate of sputum culture in patients with multi-  Dis,2020,71(4):1047-1054. DOI:10.1093/cid/ciz915.
   87   88   89   90   91   92   93   94   95   96   97